Anti-inflammatory Effects of Botulinum Toxin Type A in a Complete Freund’s Adjuvant-Induced Arthritic Knee Joint of Hind Leg on Rat Model
详细信息 查看全文
- 作者：Ki Yeon Yoo (1)
Hee Su Lee (1)
Young Kyung Cho (2)
You Sun Lim (1)
Yi Seul Kim (2)
Jung Hoi Koo (3)
Se Jin Yoon (4)
Jung Hwan Lee (5)
Ki Hyo Jang (6)
Sun Hong Song (3) - 关键词：Botulinum toxin type A ; Arthritis ; Iba ; 1 antibody ; IL ; 1β antibody ; Rat model
- 刊名：Neurotoxicity Research
- 出版年：2014
- 出版时间：July 2014
- 年：2014
- 卷：26
- 期：1
- 页码：32-39
- 全文大小：
- 参考文献：1. Anderson S, Krug HE, Dorman C, McGarraugh P, Frizelle S, Mahowald M (2010) Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain. J Pain Res 3:161-68 CrossRef
2. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M (2008) Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28:3689-696 CrossRef
3. Aoki KR (2001) Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248(Suppl 1):3-0 CrossRef
4. Arezzo JC (2002) Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 18:S125–S132 CrossRef
5. Bach-Rojecky L, Lackovic Z (2005) Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J 46:201-08
6. Bach-Rojecky L, Dominis M, Lackovic Z (2008) Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam Clin Pharmacol 22:503-09 CrossRef
7. Boon AJ, Smith J, Dahm DL, Sorenson EJ, Larson DR, Fitz-Gibbon PD, Dykstra DD, Singh JA (2010) Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. Phys Med Rehabil 2:268-76
8. Borodic GE, Acquadro M, Johnson EA (2001) Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 10:1531-544 CrossRef
9. Chou CL, Lee SH, Lu SY, Tsai KL, Ho CY, Lai HC (2010) Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc 73:573-80 CrossRef
10. Chung JI, Barua S, Choi BH, Min BH, Han HC, Baik EJ (2012) Anti-inflammatory effect of low intensity ultrasound (LIUS) on complete Freund’s adjuvant-induced arthritis synovium. Osteoarthr Cartil 20:314-22 CrossRef
11. DePuy T, Howard R, Keegan K, Wilson D, Kramer J, Cook JL, Childers MK (2007) Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot study. Am J Phys Med Rehabil 86:777-83
12. Dolly O (2003) Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43(Suppl 1):S16–S24 CrossRef
13. Erbguth FJ, Naumann M (1999) Historical aspects of botulinum toxin: Justinus Kerner (1786-862) and the “sausage poison- Neurology 53:1850-853 CrossRef
14. Favre-Guilmard C, Auguet M, Chabrier PE (2009) Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 617:48-3 CrossRef
15. Krug HE, Frizelle S, McGarraugh P, Mahowald ML (2009) Pain behavior measures to quantitate joint pain and response to neurotoxin treatment in murine models of arthritis. Pain Med 10:1218-228 CrossRef
16. Lim EC, Seet RC (2007) Botulinum toxin, Quo Vadis? Med Hypotheses 69:718-23 CrossRef
17. Mahowald ML, Singh JA, Dykstra D (2006) Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res 9:179-88 CrossRef
18. Mahowald ML, Krug HE, Singh JA, Dykstra D (2009) Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain. Toxicon 54:658-67 CrossRef
19. Monnier G, Tatu L, Michel F (2006) New indications for botulinum toxin in rheumatology. Jt Bone Spine 73:667-71 CrossRef
20. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S (2000) Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci 113(Pt 17):3073-084
21. Pavone F, Luvisetto S (2010) Botulinum neurotoxin for pain management: insights from animal models. Toxins 2:2890-913 CrossRef
22. Qerama E, Fuglsang-Frederiksen A, Jensen TS (2010) The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 23:602-10 CrossRef
23. Schaible HG, Ebersberger A, Von Banchet GS (2002) Mechanisms of pain in arthritis. Ann NY Acad Sci 966:343-54 CrossRef
24. Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Investig Ophthalmol 12:924-27
25. Singh JA, Mahowald ML (2009) Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Jt Bone Spine 76:190-94 CrossRef
26. Singh JA, Mahowald ML, Noorbaloochi S (2009) Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res 153:205-16 CrossRef - 作者单位：Ki Yeon Yoo (1)
Hee Su Lee (1)
Young Kyung Cho (2)
You Sun Lim (1)
Yi Seul Kim (2)
Jung Hoi Koo (3)
Se Jin Yoon (4)
Jung Hwan Lee (5)
Ki Hyo Jang (6)
Sun Hong Song (3)
1. Department of Oral Anatomy, Gangneung-Wonju National University, Gangneung, Republic of Korea
2. Department of Physiology and Neuroscience, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangneung, Republic of Korea
3. Department of Rehabilitation Medicine, Gangneung Asan Hospital, College of Medicine, University of Ulsan, Gangneung, Republic of Korea
4. Danam Rehabilitation Clinics, Seoul, Republic of Korea
5. Wooridul Spine Hospital, Seoul, Republic of Korea
6. Department of Food & Nutrition, College of Health & Welfare, Kangwon National University, Samcheok, Republic of Korea - ISSN：1476-3524
文摘
The objective of the study is to verify histopathologically the anti-inflammatory effect of botulinum toxin type A (BoNT-A) in a Complete Freund’s Adjuvant (CFA)-induced arthritic knee joint of hind leg on rat model using immunofluorescent staining of anti-ionized calcium-binding adaptor molecule 1 (Iba-1) and interleukin-1β (IL-1β) antibody. Twenty-eight experimental rats were injected with 0.1?ml of CFA solution in the knee joint of the hind leg bilaterally. Three weeks after CFA injection, the BoNT-A group (N?=?14) was injected with 20?IU (0.1?ml) of BoNT-A bilaterally while the saline group (N?=?14) was injected with 0.1?ml of saline in the knee joint of the hind leg bilaterally. One and two weeks after BoNT-A or saline injection, joint inflammation was investigated in seven rats from each group using histopathological and immune-fluorescent staining of Iba-1 and IL-1β antibody. The number of Iba-1 and IL-1β immune-reactive (IR) cells was counted in the BoNT-A and saline groups for comparison. There was a significant reduction in joint inflammation and destruction in the BoNT-A group at 1 and 2?weeks after BoNT-A injection compared with the saline group. The binding of Iba-1 and IL-1β antibody was significantly lower in the BoNT-A group than the saline group at 1 and 2?weeks after BoNT-A injection. The number of Iba-1 and IL-1β-IR cells at 1 and 2?weeks after the injection of BoNT-A were significantly different from the corresponding number of Iba-1 and IL-1β-IR cells in the saline group. To conclude, BoNT-A had an anti-inflammatory effect in a CFA-induced arthritic rat model, indicating that BoNT-A could potentially be used to treat inflammatory joint pain.